Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 304 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Taking on DNA repair to tackle cancer November 5, 2021 Mom Fights Second Round Of Breast Cancer — Weeks Later, Her... September 13, 2019 Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A October 3, 2023 Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... October 8, 2025 Load more HOT NEWS Tattoo Ink May Show Up as Suspicious Spots in Lymph Nodes... Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects EMA Recommends Granting a Marketing Authorisation for Acalabrutinib Working Outdoors in the Sunshine May Lower Your Risk of Breast...
